ROCK2 Part 2: Sam Wak­sal’s Gravi­ton pairs up with Ovid Ther­a­peu­tics in rare CNS in­di­ca­tions

Ovid Ther­a­peu­tics is tap­ping in­to Sam Wak­sal’s Cor­morant-backed Gravi­ton Bio­science to de­vel­op mul­ti­ple sec­ond-gen­er­a­tion ROCK2 in­hibitors to fol­low Wak­sal’s first go-around with Rezurock at Sanofi-ac­quired Kad­mon.

For $10 mil­lion up­front, Ovid will se­cure the rights to de­vel­op GV101 — from a $517.5 mil­lion deal Gravi­ton struck with Sino Bio­phar­ma­ceu­ti­cal’s Bei­jing Tide Phar­ma­ceu­ti­cal — as well as Gravi­ton-in­vent­ed ROCK2 in­hibitors for rare cen­tral ner­vous sys­tem in­di­ca­tions, par­tic­u­lar­ly dis­eases that can lead to seizures and spasms, the com­pa­nies said Mon­day morn­ing. Ovid’s rights ap­ply out­side of Chi­na, Hong Kong, Macau and Tai­wan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER